
Breast cancer vaccine meets Phase 1 goals; ovarian cancer CAR-T shows promising survival in Phase 1 trial
Anixa Biosciences announced successful Phase 1 results for its breast cancer vaccine, achieving all primary endpoints and immune responses in 74% of participants, with Phase 2 preparations underway. Their ovarian cancer CAR-T therapy, lira-cel, has r...

